about
Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancinA Carrier Protein Strategy Yields the Structure of DalbavancinCommunity-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update.The evolving role of chemical synthesis in antibacterial drug discovery.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Advances in MRSA drug discovery: where are we and where do we need to be?Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Inhibitors targeting on cell wall biosynthesis pathway of MRSA.Update on carbohydrate-containing antibacterial agents.Current and prospective treatments for multidrug-resistant gram-positive infections.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.The interaction of mannose binding lectin (MBL) with mannose containing glycopeptides and the resultant potential impact on invasive fungal infection.Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function.Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
P2860
Q26746208-7731B7D1-BF40-4E33-83AC-8978AA44F8F4Q26764885-6BC8F36C-EEAB-4ED7-B1DE-669E412031C6Q27677393-F9715565-34F3-462A-B7AB-BED2850FACF7Q33897606-2714DBD0-2948-44E5-9420-A8BD0852DC54Q34427652-192CDBDE-3BB2-4078-8CF1-A981D079A72CQ37077627-C325060C-604F-4ED7-A9A7-03A88DE8D554Q37112508-AC263127-4F8D-4B02-B33D-2982C2DAD6F8Q37785546-64861702-0E3B-4CEB-B737-D049E096C53AQ38035171-55CB381A-7D7B-4942-AE64-0A614EBEC935Q38089193-9AE4413C-8904-4F41-83DF-961ED9EDC538Q38123255-2CBFBF65-0B74-45CF-9917-99A463575209Q38137920-3F4A0464-B5FD-4250-BCD8-7A248F5135E5Q38314386-F0FC37FA-EBFA-42A7-84E3-72251EEED3E1Q38356990-AF8CA40B-38BE-4765-A513-ECB07431D519Q50079038-BDDDCB89-3D11-43C2-B3F9-76D6772A419DQ53779482-F4430CB8-8333-4D97-813A-9141199E30F7Q55512133-469690A0-592C-446E-BE3E-E0FB6A0E1EEC
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dalbavancin: a novel antimicrobial
@ast
Dalbavancin: a novel antimicrobial
@en
Dalbavancin: a novel antimicrobial
@nl
type
label
Dalbavancin: a novel antimicrobial
@ast
Dalbavancin: a novel antimicrobial
@en
Dalbavancin: a novel antimicrobial
@nl
prefLabel
Dalbavancin: a novel antimicrobial
@ast
Dalbavancin: a novel antimicrobial
@en
Dalbavancin: a novel antimicrobial
@nl
P2093
P2860
P3181
P1476
Dalbavancin: a novel antimicrobial
@en
P2093
P2860
P304
P3181
P356
10.1111/J.1742-1241.2007.01318.X
P407
P577
2007-05-01T00:00:00Z